[ANMCO Statement: semaglutide in cardio-nephro-metabolic disorders].

Nov 26, 2024Giornale italiano di cardiologia (2006)

ANMCO Statement on Semaglutide for Heart, Kidney, and Metabolic Conditions

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Semaglutide is associated with a reduction in major adverse cardiovascular events for overweight/obese patients at high cardiovascular risk.

The drug shows potential benefits beyond glycemic control in type 2 diabetes mellitus.
Improvements in functional capacity have been observed in heart failure patients with preserved left ventricular function.
Semaglutide may slow the progression of albuminuria and reduce chronic kidney disease risk in diabetic populations.
Its effects could be linked to anti-inflammatory properties, weight loss, blood pressure reduction, and direct renal protection.

AI simplified

Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a pivotal therapeutic agent in the management of the cardio-renal-metabolic continuum. Initially developed for glycemic control in type 2 diabetes mellitus, its benefits extend far beyond glucose regulation. Clinical trials have demonstrated semaglutide's potential to reduce major adverse cardiovascular events, particularly in overweight/obese patients with high cardiovascular risk, as well as improving functional capacity in patients suffering from heart failure with preserved left ventricular function. Additionally, it has shown promise in improving renal outcomes, such as slowing the progression of albuminuria and reducing the risk of chronic kidney disease in diabetic populations. These effects are likely due to its multifaceted mechanisms, including anti-inflammatory properties, weight reduction, blood pressure lowering, and direct renal protection. This review synthesizes current evidence on semaglutide's role in the interrelated domains of cardiovascular, renal, and metabolic health.

[ANMCO Statement: semaglutide in cardio-nephro-metabolic disorders].

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief